Kenvue (KVUE) Could Be 9% Undervalued On FDA Backing For New TYLENOL Launch

Kenvue (KVUE) has just put a new over the counter pain reliever, TYLENOL with Naproxen, in the spotlight after securing FDA approval for this dual ingredient, opioid free product.

Kenvue’s recent momentum has been mixed, with a 30 day share price return that declined 5.11% and a 90 day share price return that fell 1.60%. At the same time, the year to date share price return is up 2.94% and the 1 year total shareholder return is 1.89%, suggesting modest long term progress while near term sentiment has softened despite the TYLENOL with Naproxen launch and the recently affirmed US$0.21 quarterly dividend.

Spot potential peers to Kenvue by scanning a hand-picked group of resilient consumer-facing stocks screened for 11 resilient stocks with low risk scores.

Kenvue appears to be a solid consumer health business on paper, backed by global brands and newer products such as TYLENOL with Naproxen. The central question for investors is whether the current share price fairly reflects that strength.

Most Popular Narrative: 9% Undervalued

Against Kenvue's last close of $17.83, the most followed narrative anchors fair value at $19.50. The thesis therefore leans on modest undervaluation that depends heavily on execution and capital allocation over several years.

Accelerated innovation pipeline and shift toward consumer-centric product development (e.g., premium, natural, and dye-free options in Tylenol and oral health) aligns the portfolio with sustained demand for preventative health and wellness products, supporting resilience in core revenues and higher average selling prices.

See why 55 investors see Kenvue as 9% undervalued.

Result: Fair Value of $19.50 (UNDERVALUED)

Still, Kenvue faces real pressure if e-commerce execution lags competitors or if complexity across brands and regions continues to affect efficiency and profitability.

Find out about the key risks to this Kenvue narrative.

Next Steps

Mixed signals around Kenvue's valuation and product momentum only matter if you put them in your own context. Stress test the numbers, weigh the upside and downside, then decide where you stand with 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Kenvue?

Do not stop with Kenvue. Broaden your watchlist with focused stock shortlists so you are not relying on a single story to shape your portfolio.

• Target reliable income streams by scanning companies screened as 6 dividend fortresses.
• Spot potential bargains early by reviewing a curated set of 16 high quality undiscovered gems.
• Prioritise resilience and capital protection by researching a list of solid balance sheet and fundamentals (22 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com